Rios Colombo N, Ross R, Hill C
Gut Microbes. 2025; 17(1):2451081.
PMID: 39817466
PMC: 11740676.
DOI: 10.1080/19490976.2025.2451081.
Lee C, Yan X, Wu H, Ko W, Tsai P, Hung Y
Front Microbiol. 2024; 15:1418817.
PMID: 39228379
PMC: 11368742.
DOI: 10.3389/fmicb.2024.1418817.
Walsh L, Lavelle A, OConnor P, Hill C, Ross R
Gut Microbes. 2024; 16(1):2342583.
PMID: 38722061
PMC: 11085969.
DOI: 10.1080/19490976.2024.2342583.
Adukauskiene D, Mickus R, Dambrauskiene A, Vanagas T, Adukauskaite A
Antibiotics (Basel). 2024; 13(1).
PMID: 38247610
PMC: 10812669.
DOI: 10.3390/antibiotics13010051.
Spigaglia P, Mastrantonio P, Barbanti F
Adv Exp Med Biol. 2024; 1435:169-198.
PMID: 38175476
DOI: 10.1007/978-3-031-42108-2_9.
Clostridium difficile Infection During Palliative Capecitabine Chemotherapy: A Case Report.
Bhattar K, Agrawal P
Cureus. 2022; 14(7):e27102.
PMID: 36004012
PMC: 9392427.
DOI: 10.7759/cureus.27102.
The Current Knowledge on Infection in Patients with Inflammatory Bowel Diseases.
Boeriu A, Roman A, Fofiu C, Dobru D
Pathogens. 2022; 11(7).
PMID: 35890064
PMC: 9323231.
DOI: 10.3390/pathogens11070819.
Characterization of a outbreak caused by PCR ribotype 046, associated with increased mortality.
Magnusson C, Mernelius S, Bengner M, Noren T, Serrander L, Forshell S
Emerg Microbes Infect. 2022; 11(1):850-859.
PMID: 35240942
PMC: 8942542.
DOI: 10.1080/22221751.2022.2049981.
Fecal Microbiota Transplant in Severe and Non-Severe Infection. Is There a Role of FMT in Primary Severe CDI?.
Popa D, Neamtu B, Mihalache M, Boicean A, Banciu A, Banciu D
J Clin Med. 2021; 10(24).
PMID: 34945118
PMC: 8707415.
DOI: 10.3390/jcm10245822.
To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors.
Sahu K, Mishra A, Jindal V, Siddiqui A, George S
Heliyon. 2021; 7(12):e08450.
PMID: 34926847
PMC: 8646976.
DOI: 10.1016/j.heliyon.2021.e08450.
Raja 42, a novel gamma lactam compound, is effective against Clostridioides difficile.
Fong A, Ross M, Boudreau J, Nokhbeh R, Tilbe K, Lee H
PLoS One. 2021; 16(9):e0257143.
PMID: 34492076
PMC: 8423298.
DOI: 10.1371/journal.pone.0257143.
Teicoplanin Suppresses Vegetative and Spore Outgrowth.
Ojha S, Phanchana M, Harnvoravongchai P, Chankhamhaengdecha S, Singhakaew S, Ounjai P
Antibiotics (Basel). 2021; 10(8).
PMID: 34439034
PMC: 8388965.
DOI: 10.3390/antibiotics10080984.
Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Infection.
Gonzales-Luna A, Olaitan A, Shen W, Deshpande A, Carlson T, Dotson K
Open Forum Infect Dis. 2021; 8(8):ofab365.
PMID: 34381844
PMC: 8351808.
DOI: 10.1093/ofid/ofab365.
Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of....
Bouza E, Aguado J, Alcala L, Almirante B, Alonso-Fernandez P, Borges M
Rev Esp Quimioter. 2020; 33(2):151-175.
PMID: 32080996
PMC: 7111242.
DOI: 10.37201/req/2065.2020.
Oral Vancomycin May Be Associated With Earlier Symptom Resolution Than Metronidazole for Hospitalized Children With Nonsevere Infections.
Yin J, Kociolek L, Same R, Hsu A, Amoah J, Tamma P
Open Forum Infect Dis. 2020; 6(12):ofz492.
PMID: 31950069
PMC: 6954469.
DOI: 10.1093/ofid/ofz492.
therapeutics: guidelines and beyond.
Orenstein R, Patron R
Ther Adv Infect Dis. 2019; 6:2049936119868548.
PMID: 31448117
PMC: 6693025.
DOI: 10.1177/2049936119868548.
Comparison of three current Clostridioides difficile infection guidelines: IDSA/SHEA, ESCMID, and ACG guidelines.
Thabit A, Alsolami M, Baghlaf N, Alsharekh R, Almazmumi H, Alselami A
Infection. 2019; 47(6):899-909.
PMID: 31428991
DOI: 10.1007/s15010-019-01348-9.
Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with (RAPID): a randomised placebo controlled trial.
Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A
Gut. 2018; 68(7):1224-1231.
PMID: 30254135
PMC: 6582824.
DOI: 10.1136/gutjnl-2018-316794.
A Retrospective Study Analyzing the Appropriateness of Initial Treatment of in Patients with Active Malignancy.
Fisher A, Khanal P, Gniado E, Khaddour L, Orosey M, Hader I
Gastroenterol Res Pract. 2018; 2018:7192728.
PMID: 29991944
PMC: 5994314.
DOI: 10.1155/2018/7192728.
Recent Progress for the Effective Prevention and Treatment of Recurrent Infection.
Ramsay I, Brown N, Enoch D
Infect Dis (Auckl). 2018; 11:1178633718758023.
PMID: 29535530
PMC: 5844436.
DOI: 10.1177/1178633718758023.